[ad_1] Robert Galbraith | Reuters The Federal Trade Commission last week allowed Amgen to move forward with its $27.8 billion acquisition of Horizon Therapeutics under a settlement agreement – a move that could have ramifications for a string of other pharmaceutical industry buyouts. Some Wall Street analysts said the FTC’s decision to settle allows the…
[ad_1] The Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California. Mario Tama | Getty Images The Federal Trade Commission on Friday said it has reached a deal with drug giant Amgen to allow the company’s $27.8 billion purchase of Horizon Therapeutics to move forward. The two companies now…
[ad_1] Robert Galbraith | Reuters Horizon Therapeutics expects its $27.8 billion sale to Amgen to close as early as the end of the third quarter, earlier than previously planned — if the Federal Trade Commission’s attempt to block the deal fails — according to a document filed Thursday with the Securities and Exchange Commission. The…
[ad_1] A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange, July 29, 2019. Brendan McDermid | Reuters Pfizer plans to raise $31 billion through a debt offering to fund its proposed acquisition of cancer drug maker Seagen, for what would be its largest takeover since 2009,…
[ad_1] The Federal Trade Commission on Tuesday filed a lawsuit seeking to block drug giant Amgen‘s $27.8 billion acquisition of Horizon Therapeutics, arguing that the deal would “stifle competition” in the pharmaceutical industry. The FTC said that the deal would allow Amgen to “entrench the monopoly positions” of two of Horizon’s fast-growing medications: the thyroid…
